Clinical Trials Logo

Multiple Myeloma, Neoplasms clinical trials

View clinical trials related to Multiple Myeloma, Neoplasms.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01804140 Completed - Clinical trials for Multiple Myeloma, Neoplasms

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Start date: December 2012
Phase: N/A
Study type: Observational

This is a screening study to detect BRAF V600 mutation-positive patients for enrollment into clinical research studies of Zelboraf (vemurafenib). Tumor samples will be collected and analyzed from eligible patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma. All institutions with identified patients as defined by this screening protocol will have potential access to the separate vemurafenib protocol MO28072.

NCT ID: NCT01524978 Completed - Clinical trials for Multiple Myeloma, Neoplasms

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Start date: April 12, 2012
Phase: Phase 2
Study type: Interventional

This open-label, multi-center study will assess the efficacy and safety of vemurafenib in participants with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and for whom vemurafenib is deemed the best treatment option in the opinion of the investigator. Participants will receive twice daily oral doses of 960 mg vemurafenib until disease progression, unacceptable toxicity, or withdrawal of consent. The safety and efficacy of vemurafenib in combination with cetuximab in a subset of participants with colorectal cancer will also be assessed.